Simone Chevalier
- Full Professor
- 缅北强奸 Urology Director of Research
PhD
Identification of molecular drivers of prostate cancer (PCa) lethality.
This research implies 300 patients of the PROCURE PCa cohort. They donated prostate tissues at radical prostatectomy and liquid biopsies from prior to surgery and during their trajectory. The ongoing DNA and RNA sequencing of prostate tumours from 100 lethal cases and 200 of different outcomes will reveal their genomic and transcriptomic profiles. The parallel sequencing of circulating tumour (ct)DNA and overexpressed transcripts in longitudinally collected blood samples from selected lethal cases will identify new molecules initially present in tumours or else, appearing in late stages and coming from metastases. Additional molecules (methylated DNA, lipids, steroids, proteins) will be profiled in the same patients. This comprehensive understanding of lethal PCa will translate in patient-tailored signatures, and allow more specific therapeutic interventions to impact on PCa death.
- Liquid biopsies to identify new markers of lethal prostate cancer
- Prostate cancer progression.
- Intra-tumoral heterogeneity and diversity of prostate cell subtypes
- Prostate physiopathology
- Prostate cancer
- Growth factors
- Signaling pathways
- Tyrosine kinases
- Tanscription factors
- Androgen-sensitivity/insensitivity
- Castration-resistance
- Prostate cancer progression
-The Cancer Genome Atlas Research Network (312 authors with PROCURE Investigators A. Aprikian, S. Chevalier and F. Brimo from the MUHC-RI). The molecular taxonomy of primary prostate cancer. Cell. 2015 Nov 5;163(4):1011-25.
-Ebrahimizadeh W, Guerard K-P, Rouzbeh S, Bramhecha Y, Sclarata E, Brimo F, Patel P, Jamaspishvili T, Aprikian AG, Berman DM, Bartlett JMS, Chevalier S/co-director, Lapointe J. Design and development of a fully synthetic MLPA based probe mix for detection of copy number alterations in prostate cancer formalin-fixed paraffin embedded tissue samples. J Mol. Diagn. 2020 Oct;22(10):1246-1263. doi: 10.1016/j.jmoldx.2020.07.003. Epub 2020 Aug 4 2020
-Derderian S, Vesval Q, Wissing MD, Hamel L, C么t茅 N, Vanhuyse M, Ferrario C, Bladou, F, Aprikian A, Chevalier S.Liquid biopsy-based targeted gene screening highlights tumour cell subtypes in patients with advanced prostate cancer. Clin Transl Sci. Nov;15(11):2597-2612, 2022. PMID: 36172886 DOI: 10.1111/cts.13372
-Ebrahimizadeh W, Gu茅rard KP, Rouzbeh S, Scarlata E, Brimo F, Patel PG, Jamaspishvili T, Hamel L, Aprikian A, Lee AY, Berman DM, Bartlett JMS, Chevalier S/co-director, Lapointe J. A DNA copy number alteration classifier as a prognostic tool for prostate cancer patients. British J Cancer, 2023 Jun;128(12):2165-2174. doi: 10.1038/s41416-023-02236-8. Epub 2023 Apr 10.
-Derderian S, Benidir T, Scarlata E, Altaylouni T, Hamel L, Zouanat FZ, Brimo F, Aprikian A, Chevalier S Cell-by-cell quantification of the androgen receptor expression in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression. J Pathol: Clin Res, 2023 Jul;9(4):285-301. doi: 10.1002/cjp2.319. Epub 2023 Apr 18.
